Bevacizumab for Macular Edema from Branch Retinal Vein Occlusion
Author Information
Author(s): Mathias Abegg, Christoph Tappeiner, Ute Wolf-Schnurrbusch, Daniel Barthelmes, Sebastian Wolf, Johannes Fleischhauer
Primary Institution: Department of Ophthalmology, Inselspital, University of Bern, Switzerland
Hypothesis
The study evaluates the effect of Bevacizumab treatment in patients with macular edema induced by branch retinal vein occlusion.
Conclusion
Intravitreal Bevacizumab is an effective and lasting treatment for macular edema after branch retinal vein occlusion.
Supporting Evidence
- Visual acuity improved significantly 4 to 6 weeks after Bevacizumab treatment.
- Retinal thickness decreased significantly after treatment.
- 41% of injected eyes showed a visual improvement of at least 2 lines after injection.
- BCVA remained unchanged in 53% of patients.
- Treatment effects lasted for several months after Bevacizumab use.
Takeaway
This study shows that a medicine called Bevacizumab can help people see better when they have swelling in their eyes caused by a blocked vein.
Methodology
Retrospective analysis of 32 eyes in 32 patients with fluorescein angiography proven branch retinal vein occlusion and Bevacizumab treatment.
Limitations
The study design was retrospective and did not include a control group.
Participant Demographics
Median age of patients was 65 years, with 15 females and 17 males.
Statistical Information
P-Value
<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website